What Medserve does

MedServe (legally NSIA Advanced Medical Services Limited) is a Nigerian healthcare provider and wholly-owned subsidiary of the Nigeria Sovereign Investment Authority (NSIA), operating a network of advanced medical centres that deliver oncology and diagnostic services domestically. Its portfolio comprises three operational facilities: MedServe LUTH Cancer Centre (MLCC) in Lagos—a high-volume outpatient oncology centre co-located with the Lagos University Teaching Hospital and equipped with Varian Halcyon linear accelerators and Nigeria's only 3D-HDR brachytherapy system; MedServe Umuahia Diagnostic Centre (MUDC); and MedServe Kano Diagnostic Centre (MKDC). Collectively, the network has cumulatively treated over 13,000 cancer patients at MLCC and run more than 1.3 million laboratory tests and 70,000+ imaging studies across the diagnostic centres. The underlying technology stack combines capital-intensive clinical hardware (1.5T MRI, 160-slice CT, 4D ultrasound, digital X-ray, Beckman Coulter and Sysmex analysers) with Laboratory Information Systems (LIS) and PACS for electronic result management; MLCC is staffed by ten clinical and radiation oncologists, the highest concentration in a single West African site.

The business model is a multi-revenue-stream healthcare services operation: per-treatment fees for oncology (radiotherapy, chemotherapy, brachytherapy, immunotherapy, hormonal therapy, CT simulation), per-test fees for diagnostic imaging and laboratory services, premium-priced international patient packages (medical tourism with concierge, visa, and airport services), DNA paternity testing, and HMO/corporate health-plan channel partnerships. An Indigent Support Program (NISP) provides subsidised access for underserved patients. Distribution is direct via on-site centres, supplemented by online booking, telemedicine, and HMO networks; international patients are reached via dedicated concierge marketing. The company reports research-driven differentiation, including the IAEA/ESTRO HYPOAfrica trial, the University of Chicago/Roche ARETTA HER2+ breast cancer study, and 15+ active research projects, and has secured ESMO Designated Centre status (2025-2027) plus three consecutive NHEA Most Outstanding Oncology Centre awards (2023-2025).

Name

Medserve

Legal name

NSIA Advanced Medical Services Limited

Website

https://medserve.ng

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

MedServe is a Nigerian sovereign-backed healthcare operator (NSIA subsidiary) running three advanced oncology and diagnostic centres—Lagos, Umuahia, and Kano—serving cancer and general diagnostic patients with Halcyon radiotherapy, 3D-HDR brachytherapy, MRI, CT, and full laboratory services, while executing a $280M expansion to 33 facilities.

Ownership category

akta.pro rank

Product category

Oncology and Diagnostic Healthcare Services

NAICS

Medical Laboratories (621511), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Oncology services
• Diagnostic imaging
• Radiation therapy
• Medical laboratory testing
• Cancer care

Headquarters

HQ city

Abuja

HQ country

Nigeria

HQ region

Africa

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Oncology Treatment Services: Revenue generated from cancer treatment services including radiotherapy, chemotherapy, immunotherapy, brachytherapy, and hormonal therapy. MLCC serves approximately 2,500 new cancer cases annually with over 12,000 unique patients treated since 2019. Payment accepted via self-payment (debit card, bank transfer, direct deposit), HMO coverage, and international insurance.
2. Diagnostic Services: Revenue from comprehensive imaging and laboratory diagnostic services including MRI, CT scans, X-rays, ultrasound, mammography, blood tests, microbiology, and molecular/genetic testing. MUDC has conducted over 653,000 laboratory tests and 34,000 X-rays; MKDC has processed over 676,000 laboratory tests and 38,000 digital X-rays.
3. International Patient Services: Premium medical tourism services for international patients including priority consultation timing, priority radiotherapy/chemotherapy scheduling in private suites, complimentary virtual follow-ups, psycho-oncology consultations, nutrition support, VIP lounge access, visa guidance, and airport pickup services.
4. Paternity and Specialised Testing: DNA-based paternity testing services including prenatal options, with results typically available within two weeks. Results delivered in person with utmost confidentiality.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Medserve operates a national network of advanced medical facilities in Nigeria delivering oncology and diagnostic services. The flagship MedServe LUTH Cancer Centre (MLCC) provides comprehensive cancer treatment including radiotherapy, chemotherapy, brachytherapy, immunotherapy, hormonal therapy, and CT simulation, supported by international second-opinion partnerships. The MedServe Kano Diagnostic Centre (MKDC) and MedServe Umuahia Diagnostic Centre (MUDC) provide advanced imaging (MRI, CT, X-ray, ultrasound, mammography) and full laboratory diagnostics under ISO 15189 standards, with additional offerings in clinical trials, paternity testing, and international patient concierge services.

Product overview

Medserve operates as a network of specialized medical facilities across Nigeria, comprising three distinct service lines: MedServe LUTH Cancer Centre (MLCC) for advanced oncology services, and two diagnostic centres (MKDC in Kano and MUDC in Umuahia) providing comprehensive imaging and laboratory diagnostics. The MLCC offers cancer care including radiotherapy (Halcyon system), brachytherapy, chemotherapy, immunotherapy, and CT simulation for treatment planning. The diagnostic centres provide MRI (1.5 Tesla), CT (160-slice), digital X-ray, 4D ultrasound, mammography, ECG/ECHO, and full laboratory services. Additional offerings include clinical trials, paternity testing, and international patient services. The company is owned by NSIA and operates under a Healthcare Expansion Programme to establish 23 additional diagnostic centres, 3 oncology centres, and 7 cardiac catheterization laboratories nationwide.

Differentiator

Problem solved

Functional benefit

Products and services

• MedServe LUTH Cancer Centre (MLCC) Outpatient oncology centre in Lagos delivering radiotherapy, chemotherapy, brachytherapy, immunotherapy, hormonal therapy, and CT simulation. Equipped with Halcyon linear accelerators and Nigeria's only 3D-HDR brachytherapy facility; staffed by ten clinical and radiation oncologists.
• MedServe Umuahia Diagnostic Centre (MUDC) 24/7 diagnostic centre in Umuahia providing MRI (1.5 Tesla), 160-slice CT, digital X-ray, 4D ultrasound, mammography, ECG, ECHO, and comprehensive laboratory testing operating on ISO 15189:2022 standard.
• MedServe Kano Diagnostic Centre (MKDC) Round-the-clock diagnostic centre in Kano with Siemens Essenza 1.5T MRI, digital X-ray, 3D/4D ultrasound, and comprehensive laboratory services including Beckman Coulter and Sysmex analysers.
• Radiotherapy External beam radiation therapy using linear accelerators (including the Halcyon system) to deliver electrons and photons to targeted cancer cells with safety and precision.
• Chemotherapy Drug treatment using over 300 chemotherapy regimens (adjuvant, neoadjuvant, and palliative) to treat various cancer types.
• Brachytherapy Nigeria's only three-dimensional high-dose-rate (3D-HDR) internal radiation therapy for cancers of the head, neck, breast, cervix, prostate, and eye with precision targeting that minimises damage to healthy cells.
• Immunotherapy Modern cancer treatment that helps the body's immune system recognise and fight cancer cells, including checkpoint inhibitors, monoclonal antibodies, and cancer vaccines.
• CT Simulation CT-based imaging that maps tumours and surrounding organs in 3D for precise radiation treatment planning using specialised patient-positioning devices.
• Clinical Trials Oncology clinical research programme including the IAEA-sponsored HYPOAfrica trial for hypofractionated radiotherapy in prostate cancer and the ARETTA HER2-positive breast cancer study with University of Chicago and Roche.
• Magnetic Resonance Imaging (MRI) 1.5 Tesla MRI imaging using magnetic fields and radio waves to create detailed images of organs, bones, and tissues for diagnosis of cancer, heart disease, and other conditions.
• Computed Tomography (CT) 160-slice CT scanner delivering 50% less radiation with high-quality cross-sectional imaging of head, chest, and abdominal areas, including CT urography, CT angiography, cardiac CT, and virtual colonoscopy.
• X-Ray Imaging Digital X-ray covering plain and special procedures with minimal radiation exposure, including mammography for breast cancer screening/diagnosis and hysterosalpingography for fertility assessment.
• Ultrasound 4D diagnostic ultrasound covering obstetrics, abdominal and pelvic organs, breast, thyroid, prostate, and cardiac imaging including Doppler studies and echocardiograms.
• Cardiac Diagnostics Non-invasive cardiac assessment including electrocardiogram (ECG), echocardiogram (ECHO), and cardiac MRI/CT imaging for detecting heart disease, valve problems, and tumours.
• Laboratory Services Comprehensive laboratory testing including full blood count, immunoassays, serology, microscopy, morphology, microbiology, parasitology, molecular/genetic testing, cholesterol profiling, and glucose testing.
• Paternity Testing DNA-based paternity testing for legal, immigration, or personal reasons, including prenatal options, with results typically available within two weeks and delivered in person with utmost confidentiality.
• International Patient Services Premium concierge services for international cancer patients including priority consultations, priority radiotherapy/chemotherapy scheduling in private suites, complimentary virtual follow-ups, psycho-oncology and dietician consultations, VIP lounge access, visa guidance, airport pickup, and accommodation support.

Quantifiable outcome

• Over 13,000 unique cancer patients treated since 2019 with approximately 2,500 new cases annually at MLCC
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• Varian Medical SystemscoreTechnology or IntegrationVarian provides the advanced radiotherapy technology powering MedServe's oncology services, including the Halcyon linear accelerator system and linear accelerators capable of delivering electrons and photons for treating various cancer types. This partnership enables precision radiotherapy treatment capabilities previously unavailable in Nigeria.
• Memorial Sloan Kettering Cancer Center (MSKCC)coreStrategic or Co-development PartnerMSKCC is a premier cancer research and treatment institution partnering with MedServe on breast cancer pathology second opinions and clinical knowledge exchange. Their expertise supports MedServe's position as a leading oncology centre in Africa.
• University of ChicagocoreStrategic or Co-development PartnerAcademic partnership supporting the ARETTA HER2-Positive Breast Cancer Study, working with Roche Pharmaceuticals to assess treatment response in Nigerian women. Includes working visits for knowledge exchange and collaboration on oncology research.
• University of MarylandcoreStrategic or Co-development PartnerAcademic partnership for oncology research and clinical practice collaboration, supporting MedServe's research initiatives and knowledge transfer programmes.
• Bio Ventures for Global Health (BVGH)majorStrategic or Co-development PartnerBVGH supports MedServe's mission to improve healthcare accessibility through partnership programmes that connect African healthcare institutions with global resources and expertise in cancer care.
• International Atomic Energy Agency (IAEA)coreStrategic or Co-development PartnerIAEA sponsors the HYPOAfrica trial, a clinical trial led by MedServe and one other institution to prove the efficacy of hypofractionated radiotherapy for prostate cancer. IAEA is the international organisation promoting safe and secure use of nuclear technologies.
• European Society for Radiotherapy and Oncology (ESTRO)coreStrategic or Co-development PartnerESTRO collaborates with IAEA on the HYPOAfrica trial for hypofractionated radiotherapy in prostate cancer treatment. ESTRO is the leading European radiotherapy society advancing radiation oncology practice.
• Roche PharmaceuticalsmajorStrategic or Co-development PartnerRoche supports the ARETTA study (Assessing Response to neoadjuvant Taxotere and TrAstuzumab) in Nigerian women with HER2-positive breast cancer, conducted at MedServe Lagos Centre in partnership with University of Chicago.
• Quality First (South Africa)majorImplementation/ SI/ Consulting PartnerQuality First is a South African training consultant in close partnership with MUDC for accreditation preparation. They support MUDC's journey toward COHSASA and ISO 15189 accreditation through training and consulting services.
• Quality First (South Africa)majorImplementation/ SI/ Consulting PartnerQuality First serves as consulting firm for MKDC's quality management system, issuing working SOPs for every unit, regularly updated and reviewed to ensure ISO compliance and operational excellence.
• International Finance Corporation (IFC)majorStrategic or Co-development PartnerIFC, a member of the World Bank Group, hosted MedServe at the 10th Global Private Health Conference and participated in an IFC-MedServe press conference, signalling investment and strategic support for MedServe's healthcare expansion programme.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Regional players

• Aga Khan University Hospital Nairobi: Aga Khan University Hospital in Nairobi is East Africa's leading tertiary academic hospital with comprehensive oncology, advanced diagnostics, and clinical trials. It is a regional peer for MedServe in scope of oncology services, talent concentration, and academic partnerships, though in a different geography.

Broad incumbents

• HCA Healthcare: HCA Healthcare is the largest for-profit hospital operator in the US with extensive oncology and outpatient diagnostic service lines. It represents the scaled, vertically-integrated incumbent model MedServe aspires to in the Nigerian market.
• Apollo Hospitals Enterprise: Apollo Hospitals is one of Asia's largest hospital chains with established oncology, diagnostics, and international patient services programmes. It serves as a broad incumbent comparable for MedServe's premium cancer-care positioning and inbound medical tourism ambitions.

Direct peers

• Reddington Hospital: Reddington is a Lagos-based private hospital offering advanced diagnostics, cardiology, and multi-specialty care to Nigeria's middle and upper-middle class. It overlaps directly with MedServe's diagnostic imaging and specialist consultation services in Lagos.
• St. Nicholas Hospital Lagos: St. Nicholas is a long-established multi-specialty private hospital in Lagos offering advanced diagnostics and specialist care. It is a peer for MedServe's MLCC catchment for affluent patients seeking cancer and specialty diagnostics in Lagos.
• Cedarcrest Hospitals: Cedarcrest is a multi-specialty private hospital group in Abuja and Lagos with advanced diagnostics and surgical capabilities. It competes with MedServe for affluent Nigerian patients seeking premium outpatient and specialty care in the same metropolitan catchments.
• Euracare Nigeria: Euracare operates advanced diagnostic and specialty medical centres in Lagos and Accra, offering MRI, CT, laboratory, and interventional services. It is a direct competitor to MedServe's diagnostic centres (MKDC, MUDC) for premium imaging and lab work in West Africa's commercial hubs.
• Lancet Laboratories Nigeria: Lancet Laboratories is one of Africa's largest private pathology networks, operating across Nigeria with comprehensive clinical laboratory services. It directly competes with MedServe's laboratory services at MUDC and MKDC for high-volume routine and specialised testing.

Others

• Varian Medical Systems (Siemens Healthineers): Varian (now part of Siemens Healthineers) supplies the Halcyon linear accelerators and radiotherapy software that underpin MedServe's MLCC service line. It is a key technology/infrastructure partner rather than a competitor, but its capability roadmap directly shapes MedServe's oncology offering.
• Memorial Sloan Kettering Cancer Center: MSKCC is MedServe's clinical knowledge partner for breast cancer pathology second opinions and is a global reference standard for integrated cancer care. It is an ecosystem/knowledge partner rather than a direct competitor, but represents the benchmark against which MedServe's oncology quality is positioned.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/MedServe_Ng
• YouTubeyoutube.com/@medserveluth
• Facebookweb.facebook.com/medservenigeria?mibextid=wwXIfr&rdid=5spIAAIM6FiBhI3c&share_url=https%3A%2F%2Fweb.facebook.com%2Fshare%2F1Bd2TXkPUW%2F%3Fmibextid%3DwwXIfr%26_rdc%3D1%26_rdr#
• LinkedInlinkedin.com/company/medserve-nsia-advanced-medical-services-limited
• Instagraminstagram.com/medserveng?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medserve